Abstract
α-Synuclein is a soluble, natively unfolded protein that is highly enriched in the presynaptic terminals of neurons in the central nervous system. Interest in α-synuclein has increased markedly following the discovery of a relationship between its dysfunction and several neurodegenerative diseases, including Parkinsons disease. The physiological functions of α-synuclein remain to be fully defined, although recent data suggest a role in regulating membrane stability and neuronal plasticity. In addition, there is increasing evidence pointing to phosphorylation as playing an important role in the oligomerization, fibrillogenesis, Lewy body formation, and neurotoxicity of α-synuclein in Parkinsons disease. Immunohistochemical and biochemical studies reveal that the majority of α-synuclein within inclusions from patients with Parkinsons disease and other synucleinopathies is phosphorylated at Ser129. α-Synuclein can be phosphorylated in vitro also at Ser87, and three C-terminal tyrosine residues (Tyr125, Tyr 133, and Tyr136). Tyrosine 125 phosphorylation diminishes during the normal aging process in both humans and flies. Notably, cortical tissue from patients with Parkinsons disease-related synucleinopathy dementia with Lewy bodies showed less phosphorylation at Tyr125. While phosphorylation at Ser87 is enhanced in synucleinopathies, it inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions. The possibility that α-synuclein neurotoxicity in Parkinsons disease and related synucleinopathies may result from an imbalance between the detrimental, oligomer-promoting effect of Ser129 phosphorylation and a neuroprotective action of Ser87/Tyr125 phosphorylation that inhibits toxic oligomer formation merits consideration, as will be discussed in this article.
Keywords: Parkinson's disease, α-synuclein, synucleinopathies, phosphorylation, aggregation, neurotoxicity, transgenic
CNS & Neurological Disorders - Drug Targets
Title: The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease
Volume: 9 Issue: 4
Author(s): Nadia Cavallarin, Mattia Vicario and Alessandro Negro
Affiliation:
Keywords: Parkinson's disease, α-synuclein, synucleinopathies, phosphorylation, aggregation, neurotoxicity, transgenic
Abstract: α-Synuclein is a soluble, natively unfolded protein that is highly enriched in the presynaptic terminals of neurons in the central nervous system. Interest in α-synuclein has increased markedly following the discovery of a relationship between its dysfunction and several neurodegenerative diseases, including Parkinsons disease. The physiological functions of α-synuclein remain to be fully defined, although recent data suggest a role in regulating membrane stability and neuronal plasticity. In addition, there is increasing evidence pointing to phosphorylation as playing an important role in the oligomerization, fibrillogenesis, Lewy body formation, and neurotoxicity of α-synuclein in Parkinsons disease. Immunohistochemical and biochemical studies reveal that the majority of α-synuclein within inclusions from patients with Parkinsons disease and other synucleinopathies is phosphorylated at Ser129. α-Synuclein can be phosphorylated in vitro also at Ser87, and three C-terminal tyrosine residues (Tyr125, Tyr 133, and Tyr136). Tyrosine 125 phosphorylation diminishes during the normal aging process in both humans and flies. Notably, cortical tissue from patients with Parkinsons disease-related synucleinopathy dementia with Lewy bodies showed less phosphorylation at Tyr125. While phosphorylation at Ser87 is enhanced in synucleinopathies, it inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions. The possibility that α-synuclein neurotoxicity in Parkinsons disease and related synucleinopathies may result from an imbalance between the detrimental, oligomer-promoting effect of Ser129 phosphorylation and a neuroprotective action of Ser87/Tyr125 phosphorylation that inhibits toxic oligomer formation merits consideration, as will be discussed in this article.
Export Options
About this article
Cite this article as:
Cavallarin Nadia, Vicario Mattia and Negro Alessandro, The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (4) . https://dx.doi.org/10.2174/187152710791556140
DOI https://dx.doi.org/10.2174/187152710791556140 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease
Current Alzheimer Research Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Editorial [ Medicines Da Vinci Code: Deciphering the Intricate Origins of Clinical Neurovascular Pathology K. Maiese ]
Current Neurovascular Research The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Current Pharmaceutical Design Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
Current Alzheimer Research Improving Brain Drug Targeting Through Exploitation of The Nose-to- Brain Route: A Physiological and Pharmacokinetic Perspective
Current Drug Delivery Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Effects of Opiates and HIV Proteins on Neurons: The Role of Ferritin Heavy Chain and a Potential for Synergism
Current HIV Research Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Increasing Testosterone Levels and Effects on Cognitive Functions in Elderly Men and Women: A Review
Current Drug Targets - CNS & Neurological Disorders Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
CNS & Neurological Disorders - Drug Targets In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer’s Disease Treatment
CNS & Neurological Disorders - Drug Targets Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery